About 276K results
Open links in new tab
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
BioAge Labs Files for IPO to Be Led by Goldman, Morgan Stanley
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Eli Lilly partner BioAge files for US IPO | Reuters
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
Obesity drug developer BioAge sets IPO terms (Pending:BIOA)
Eli Lilly partner BioAge files for US IPO - MSN
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity drugmaker BioAge targets $158 million in IPO